Professor Alastair Greystoke
Professor Ruth Plummer
Dr Christoph Oing
Dr Pasquale Rescigno
| Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis | 2024 |
|
Dr Christoph Oing
| Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis | 2024 |
|
Dr Christoph Oing
Dr Pasquale Rescigno
| Hyperthyroidism in non-seminomatous testicular germ cell tumors: two case reports and literature review | 2024 |
|
Dr Christoph Oing
Dr Pasquale Rescigno
| Retroperitoneal Lymph Node Dissection in Patients with Stage II Seminomatous Germ Cell Tumour | 2024 |
|
Sarah Rae
Ellie Taylor
Joseph Hoben
Dr Christoph Oing
Professor Alastair Greystoke
et al. | Social determinants of health inequalities in early phase clinical trials in Northern England | 2024 |
|
Dr Christoph Oing
| Career and Professional Development for Young Oncologists | 2023 |
|
Dr Christoph Oing
| Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty | 2023 |
|
Dr Christoph Oing
| European Association of Urology Guidelines on Testicular Cancer: 2023 Update | 2023 |
|
Dr Christoph Oing
Dr Pasquale Rescigno
| Genomic tests for persistence PSA after radical prostatectomy: smoke and mirrors or new effective tools for the clinical decision-making? | 2023 |
|
Dr Christoph Oing
| Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease | 2023 |
|
Dr Christoph Oing
| Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy | 2023 |
|
Dr Christoph Oing
| Testicular Tumors High Likelihood of Cure With Interdisciplinary Management | 2023 |
|
Dr Christoph Oing
| Therapy monitoring of neoadjuvant chemo-/radiotherapy [Therapiemonitoring der neoadjuvanten Radio‑/Chemotherapie] | 2023 |
|
Dr Christoph Oing
| Young oncologists’ perspective on the role and future of the clinician-scientist in oncology | 2023 |
|
Dr Christoph Oing
| 28/m with back pain and bulging of the abdominal wall: Preparation for the medical specialist examination: part 1 [28/m mit Rückenschmerzen und Vorwölbung der Bauchwand: Vorbereitung auf die Facharztprüfung: Fall 1] | 2022 |
|
Dr Christoph Oing
| Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients | 2022 |
|
Dr Christoph Oing
| Chromosome 3p25.3 Gain Is Associated with Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors | 2022 |
|
Dr Christoph Oing
| First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment: A comprehensive review compiled by the German Testicular Cancer Study Group | 2022 |
|
Dr Christoph Oing
| Medical specialist training internal medicine and Hematology and oncology: The second special issue is here! [Facharzt-Training Innere Medizin und Hämatologie und Onkologie: Das zweite Sonderheft ist da!] | 2022 |
|
Dr Christoph Oing
| Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review | 2022 |
|
Dr Christoph Oing
| Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy | 2022 |
|
Dr Christoph Oing
| Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry | 2022 |
|
Dr Christoph Oing
| Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival—a systematic review | 2022 |
|
Dr Christoph Oing
| Testicular tumours from a clinical point of view: What urologists and oncologists need to know from the pathologist about testicular cancer [Hodentumoren aus klinischer Sicht: Was Urolog:Innen und Onkolog:Innen von Patholog: Innen über Hodentumoren wissen müssen] | 2022 |
|
Dr Christoph Oing
| The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series | 2022 |
|
Dr Christoph Oing
| Therapy of clinical stage IIA and IIB seminoma: a systematic review | 2022 |
|
